FIELD: organic chemistry.
SUBSTANCE: invention relates to a heterocyclic compound of formula (I), an enantiomer thereof or a pharmaceutically acceptable salt thereof, wherein ring A is selected from a group consisting of structures given in the claim; R is a hydrogen atom; each R1 is identical to the other or different from it and each is selected from a hydrogen atom and a halogen atom; R2 is selected from C1-6-alkyl and C3-6-cycloalkyl, where each said C1-6-alkyl is optionally substituted with 1 group, selected from halogen atom; R3 is selected from C1-6-alkyl; each R4 is identical to the other or different from it and each is independently selected from a hydrogen atom, C3-6-cycloalkyl, a halogen atom, cyano, C2-6-alkynyl, heterocyclyl, C6-aryl, heteroaryl, -OR5, -NHC(O)OR5 and -NHC(O)NR6R7, where each said C2-6-alkynyl, heterocyclyl, C6-aryl and heteroaryl is optionally substituted with 1–2 groups selected from Rc, C1-6-alkyl, halogen-C1-6-alkyl, hydroxy-C1-6-alkyl, amino, oxo, C3-6-cycloalkyl or heterocyclyl; Rc is heteroaryl, where said heteroaryl is optionally substituted with 1 group selected from C1-6-alkyl; R5 is selected from a hydrogen atom, C1-6-alkyl and heterocyclyl, wherein said C1-6-alkyl is optionally substituted with 1 group selected from cyano and -C(O)NR6R7; R6 and R7 are identical or different from each other and each is selected from a hydrogen atom, C1-6-alkyl and C3-6-cycloalkyl; Ra and Rb are identical or different from each other and are each selected from hydrogen atom and C1-6-alkyl; m is 0, 1 or 2; n equals 0, 1 or 2; wherein C6-aryl ring may be fused with 5–6 membered heteroaryl; said heterocyclyl is 5–6 membered saturated monocyclic hydrocarbon group having one or two heteroatoms selected from nitrogen and oxygen, or said heterocyclyl ring can be condensed with pyridine; and said heteroaryl is 5–6-membered heteroaromatic system having from 1 to 4 heteroatoms selected from nitrogen, oxygen and sulfur, or said heteroaryl ring can be condensed with phenyl or pyridine. Invention also relates to an intermediate compound of formula (V), a method of producing the desired compound from a compound of formula (V), a pharmaceutical composition based on the compound of formula (I), use of a compound of formula (I) or a composition based thereon, as well as a method of treating a estrogen receptor mediated disease.
EFFECT: novel condensed piperidine derivatives useful as an estrogen receptor modulator in the treatment of estrogen receptor-mediated or estrogen-dependent diseases or conditions are obtained.
21 cl, 3 tbl, 103 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BENZOPIPERIDINE DERIVATIVE, A METHOD FOR PRODUCTION THEREOF AND MEDICAL USE THEREOF | 2016 |
|
RU2727705C1 |
| C-ARYL GLUCOSIDE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | 2011 |
|
RU2606501C2 |
| ESTROGEN RECEPTOR MODULATORS | 2017 |
|
RU2738646C2 |
| INDAZOLE DERIVATIVE, METHOD FOR PREPARATION AND PHARMACEUTICAL USE THEREOF | 2020 |
|
RU2817737C2 |
| TETRAHYDROPYRIDO[3,4-B]INDOLE DERIVATIVES USEFUL IN TREATMENT OF CANCER | 2014 |
|
RU2664109C2 |
| OXASPIRO DERIVATIVE, A METHOD FOR PRODUCTION THEREOF AND USE THEREOF IN MEDICINES | 2016 |
|
RU2733373C2 |
| OXOPICOLINAMIDE DERIVATIVE, A METHOD FOR PRODUCTION THEREOF AND PHARMACEUTICAL USE THEREOF | 2017 |
|
RU2742771C2 |
| IMIDAZOISOINDOLE DERIVATIVE, METHOD FOR PRODUCTION THEREOF AND MEDICAL USE | 2016 |
|
RU2717577C2 |
| METHOD FOR PREDICTING THE THERAPEUTIC EFFECT OF AN LSD 1INHIBITOR BASED ON THE INSM1 EXPRESSION | 2018 |
|
RU2789449C2 |
| LIGAND CONJUGATE WITH CYTOTOXIC DRUG PREPARATION, METHOD AND APPLICATION THEREOF | 2016 |
|
RU2708461C2 |
